Liu Qian, Wang Xin, Fang Zhi-Ting, Zhao Jun-Ning, Rui Xue-Xiang, Zhang Bing-Ge, He Ye, Liu Rui-Juan, Chen Jian, Chai Gao-Shang, Liu Gong-Ping
Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry of China/Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China.
Autophagy. 2025 Apr;21(4):807-826. doi: 10.1080/15548627.2024.2431472. Epub 2024 Dec 24.
Alzheimer disease (AD), a prevalent neurodegenerative condition in the elderly, is marked by a deficit in macroautophagy/autophagy, leading to intracellular MAPT/tau accumulation. While ISG15 (ISG15 ubiquitin like modifier) has been identified as a regulator of selective autophagy in ataxia telangiectasia (A-T), its role in AD remains unexplored. Our study reveals elevated ISG15 levels in the brains of patients with sporadic AD and AD models and . ISG15 overexpression in cells and the hippocampus inhibited HDAC6 (histone deacetylase 6) activity through C-terminal LRLRGG binding to HDAC6. Consequently, this increased CTTN (cortactin) acetylation, disrupted CTTN and F-actin recruitment to lysosomes, and impaired autophagosome (AP)-lysosome (LY) fusion. These disruptions led to MAPT/tau accumulation, synaptic damage, neuronal loss, and cognitive deficits. Conversely, ISG15 knockdown in our HsMAPT (human MAPT) pathology model restored HDAC6 activity, promoted AP-LY fusion, and improved cognitive function. This study identifies ISG15 as a key regulator of autophagic flux in AD, suggesting that targeting ISG15-mediated autophagy could offer therapeutic potential for AD.: AAV: adeno-associated virus; AD: Alzheimer disease; ALP: autophagy-lysosomal pathway; ANOVA: analysis of variance; AP: autophagosome; BafA1: bafilomycin A; CHX: cycloheximide; CQ: chloroquine; CTTN: cortactin; FC: fear conditioning; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GRIN/NMDARs: N-methyl-D-aspartate glutamate ionotropic receptor NMDA types; HDAC6: histone deacetylase 6; HEK293: human embryonic kidney 293; HsMAPT: human MAPT; IF: immunofluorescence; IHC: immunohistochemistry; IP: immunoprecipitation; ISG15: ISG15 ubiquitin like modifier; LAMP1: lysosomal associated membrane protein 1; LY: lysosome; MAPT: microtubule associated protein tau; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MWM: Morris water maze; NOR: novel object recognition; SQSTM1/p62: sequestosome 1; ZnF UBP: zinc finger ubiquitin-binding protein.
阿尔茨海默病(AD)是老年人中一种常见的神经退行性疾病,其特征是巨自噬/自噬功能缺陷,导致细胞内微管相关蛋白tau(MAPT/tau)积累。虽然ISG15(ISG15泛素样修饰因子)已被确定为共济失调毛细血管扩张症(A-T)中选择性自噬的调节因子,但其在AD中的作用仍未被探索。我们的研究揭示了散发性AD患者大脑和AD模型中ISG15水平升高。细胞和海马体中ISG15的过表达通过其C末端的LRLRGG与组蛋白去乙酰化酶6(HDAC6)结合来抑制HDAC6的活性。因此,这增加了皮层肌动蛋白(CTTN)的乙酰化,破坏了CTTN和丝状肌动蛋白(F-actin)向溶酶体的募集,并损害了自噬体(AP)与溶酶体(LY)的融合。这些破坏导致MAPT/tau积累、突触损伤、神经元丢失和认知缺陷。相反,在我们的人类微管相关蛋白tau(HsMAPT)病理模型中敲低ISG15可恢复HDAC6活性,促进AP-LY融合,并改善认知功能。本研究确定ISG15是AD中自噬流的关键调节因子,表明靶向ISG15介导的自噬可能为AD提供治疗潜力。:腺相关病毒(AAV);阿尔茨海默病(AD);自噬-溶酶体途径(ALP);方差分析(ANOVA);自噬体(AP);巴弗洛霉素A1(BafA1);放线菌酮(CHX);氯喹(CQ);皮层肌动蛋白(CTTN);恐惧条件反射(FC);甘油醛-3-磷酸脱氢酶(GAPDH);N-甲基-D-天冬氨酸谷氨酸离子型受体NMDA亚型(GRIN/NMDARs);组蛋白去乙酰化酶6(HDAC6);人胚肾293(HEK293);人类微管相关蛋白tau(HsMAPT);免疫荧光(IF);免疫组织化学(IHC);免疫沉淀(IP);ISG15泛素样修饰因子(ISG15);溶酶体相关膜蛋白1(LAMP1);溶酶体(LY);微管相关蛋白tau(MAPT);微管相关蛋白1轻链3(MAP1LC3/LC3);莫里斯水迷宫(MWM);新物体识别(NOR);聚集体蛋白1(SQSTM1/p62);锌指泛素结合蛋白(ZnF UBP)